Form 4: Verrica Pharmaceuticals Director Acquires Stock Options

Verrica Pharmaceuticals Inc. director Mark A. Prygocki Sr. acquired 16,000 stock options with an exercise price of $6.04.

Summary

• Mark A. Prygocki Sr., a Director at Verrica Pharmaceuticals Inc., was granted 16,000 stock options on June 5, 2026.
• These options have an exercise price of $6.04 per share.
• The underlying securities are common stock.
• The options are set to expire on June 4, 2036.
• Vesting of these options will occur in 12 equal monthly installments starting July 5, 2026, with full vesting by the next annual stockholder meeting, contingent on continued service as a director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports a standard compensation event for a director rather than providing operational or financial performance updates.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The exercise price of $6.04 suggests a potential for upside if the stock price increases above this level.

Negatives

• The filing solely reports the grant of options and does not provide information on the company's financial performance or operational status, which could be viewed negatively by investors seeking broader updates.

Risks

• The vesting schedule for the options is contingent on continued service as a director, introducing a risk of forfeiture if the director's tenure ends before full vesting.
• The value of the options is directly tied to the future stock price performance of Verrica Pharmaceuticals, which is subject to market volatility and company-specific risks.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the director's continued service, with vesting scheduled to complete by the next annual stockholder meeting.

Industry Context

StockSavvy.ai notes that the grant of stock options to a director is a common practice in the pharmaceutical industry as a form of long-term incentive compensation, aligning director interests with shareholder value.

Stakeholder Impact

• Shareholders: The grant of options to a director can be viewed positively as it aligns management incentives with stock performance, but it also represents potential future dilution if exercised.

Next Steps

• The director will receive monthly installments of vested options starting July 5, 2026.
• Full vesting of options is expected by the date of the next annual stockholder meeting, subject to continued service.

Key Dates

Keywords

Verrica Pharmaceuticals, VRCA, Form 4, Stock Options, Director Compensation, Securities Ownership, Insider Trading, Equity Awards